IMMX
Q4 2026 EPS Estimate
$-0.18
Nov 6, 2026
FY2029E EPS$0.07
FY2030E EPS$1.51

Analyst Sentiment

Wall St. Consensus
Buy
5 analysts·Limited coverage
75
Score
5 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
5100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$19.00
+36.0%
Consensus
$22.00
+57.5%
Bull
$25.00
+79.0%
12-Month Target Range5 analysts
$19.00$22.00$25.00
Current $13.97Consensus
Current Price
$13.97
Upside to Consensus
$8.03

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+90.28%
EPS
FY2028
Rev+550.98%
EPS
FY2029
Rev+90.37%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$12M$23M$150M$286M$458M
Low$6M$3M$88M$140M$224M
High$22M$42M$270M$516M$827M
EBITDA Avg$-26M$-67M$-20M$3M$63M
Low$-33M$-74M$-25M$1M$21M
High$-19M$-4M$-16M$6M$129M
EBIT Avg$-26M$-67M$-21M$3M$63M
Low$-33M$-74M$-25M$979,831$21M
High$-19M$-5M$-16M$6M$129M
Net Income Avg$-26M$-67M$-21M$2M$50M
Low$-33M$-74M$-25M$774,067$17M
High$-19M$-5M$-16M$5M$102M
EPS Avg$-0.74$-0.90$-0.67$0.07$1.51
Low$-1.01$-2.25$-0.77$0.02$0.51
High$-0.57$-0.14$-0.48$0.14$3.09
Analysts (Rev / EPS)6 / 75 / 65 / 32 / 12 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$32M$49M
Low$32M$49M
High$32M$49M
EBITDA Avg$-16M$-12M
Low$-16M$-12M
High$-16M$-12M
EBIT Avg$-16M$-12M
Low$-16M$-12M
High$-16M$-12M
Net Income Avg$-12M$-12M$-15M$-18M$-16M$-12M
Low$-13M$-13M$-15M$-18M$-16M$-12M
High$-11M$-11M$-15M$-18M$-16M$-12M
EPS Avg$-0.19$-0.19$-0.23$-0.28$-0.25$-0.19
Low$-0.21$-0.21$-0.23$-0.28$-0.25$-0.19
High$-0.17$-0.17$-0.23$-0.28$-0.25$-0.19
Analysts (Rev / EPS) / 5 / 4 / 1 / 11 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Aug 11, 2026Morgan Stanley
Immix Biopharma price target lowered to $19 from $20 at Morgan Stanley
Target:$19.00
+88.6%from $10.07
Aug 10, 2026H.C. Wainwright
Immix Biopharma price target raised to $25 from $20 at H.C. Wainwright
Target:$25.00
+157.2%from $9.72
May 22, 2026H.C. Wainwright
Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright
Target:$20.00
+124.3%from $8.91
Mar 27, 2026H.C. Wainwright
Immix Biopharma price target raised to $15 from $12 at H.C. Wainwright
Target:$15.00
+84.0%from $8.15
Feb 9, 2026Mizuho Securities
Immix Biopharma initiated with an Outperform at Mizuho
Target:$14.00
+107.7%from $6.74
Dec 9, 2025H.C. Wainwright
Immix Biopharma price target raised to $12 from $8 at H.C. Wainwright
Target:$12.00
+88.1%from $6.38
Jul 1, 2024H.C. Wainwright
Immix Biopharma initiated with a Buy at H.C. Wainwright
Target:$7.00
+253.5%from $1.98
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.